SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 11, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On September 11, 1997, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced today its subsidiary, IDT, Inc., in
conjunction with HemoCleanse, Inc., has entered into an agreement
with the University of Texas Medical Branch at Galveston (UTMB)
to begin a human clinical trial in October 1997. The trial will
utilize the ThermoChem System and disposables to deliver
extracorporeal whole-body hyperthermia (WBH) to treat patients
with metastatic non-small cell lung cancer (NSCLC). The
ThermoChem System was formerly known as the BioLogic-HT System.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: September 11, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide
Susan Taylor
1.412.429.0673 phone
1.412.279.9455 phone
1.412.279.9690 fax
1.412.279.9447 fax
BIOCONTROL SUBSIDIARY, IDT, TO CONDUCT CANCER STUDY WITH THE
UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON
Pittsburgh, PA - September 11, 1997 - Biocontrol Technology,
Inc. (Nasdaq:BICO) announced today that its subsidiary, IDT,
Inc., in conjunction with HemoCleanse, Inc., has entered into an
agreement with the University of Texas Medical Branch at
Galveston (UTMB) to begin a human clinical trial in October 1997.
The trial will utilize the ThermoChem System and disposables to
deliver extracorporeal whole-body hyperthermia (WBH) to treat
patients with metastatic non-small cell lung cancer (NSCLC). Non-
small cell lung cancer is a combination of at least three
different malignant cell structures found in the tissues of the
lungs.
The ThermoChem System was formerly known as the BioLogic-HT
System.
Lung cancer remains a major cause of cancer morbidity and
mortality in the United States, with an estimated 177,000 new
cases of lung cancer in 1996, according to the American Cancer
Society. One of the objectives of the clinical trial is to evaluate
the ThermoChem System for the use in the treatment of metastatic
NSCLC with regard to patient selection, tumor response, patient
performance status, and patient survival. The follow-up of the
patients is patterned after the Southwest Oncology Group
protocols, which are considered state-of-the-art studies to
follow response of cancer to the therapy. With current treatment
modalities, including radiation therapy, chemotherapy, and
surgery, only limited relief from the disease is realized and
patient survival extends to only approximately 15 months beyond
treatment.
The study will be conducted at the General Clinical Research
Center (GCRC) at UTMB, which is supported by the National
Institutes of Health (NIH). This is the only WBH study for
metastatic NSCLC approved by the FDA.
WBH is a therapy in which the core body temperature is
raised to 42.5 degrees C for one hour or more by direct
extracorporeal heating of the blood.
The ThermoChem System can effectively remove a wide range of
chemicals and toxins from the blood, while maintaining a balance
of electrolytes and important nutrients, which the company
believes is necessary to safely administer whole-body
hyperthermia.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, Pennsylvania and is involved in the development and
manufacture of biomedical devices and environmental products.
IDT, Inc., a wholly-owned subsidiary of Biocontrol also located
in Pittsburgh, PA, holds exclusive worldwide marketing rights to
the ThermoChem System and related disposables, while
HemoCleanse, Inc. of West Lafayette, IN, holds the exclusive
worldwide manufacturing rights.
